Medication Burden Screening to Identify Pharmacotherapy Risks

Abstract

Medication burden screening is a crucial strategy in contemporary clinical practice to identify patients at risk of adverse pharmacotherapy outcomes. With increasing polypharmacy among aging populations and those with multimorbidity, systematic screening tools can help clinicians proactively recognize and mitigate medication-related harms. This review synthesizes current evidence and guideline-based recommendations on medication burden screening, highlights pathophysiological mechanisms underpinning pharmacotherapy risks, and offers practical insights for implementation in clinical workflows.

Introduction

The complexity of modern pharmacotherapy has led to heightened concerns regarding medication burden, defined as the cumulative negative impact of multiple medications on a patient's health, function, and quality of life. Polypharmacy, commonly encountered in geriatric and chronic disease populations, increases the risk of adverse drug events (ADEs), drug-drug interactions, and therapeutic inefficacy. Medication burden screening has emerged as an evidence-based approach to proactively identify patients at risk, facilitate medication optimization, and reduce iatrogenic harm. This article provides an in-depth review of medication burden screening, with a focus on clinical applicability, underlying mechanisms, and current best practices as informed by recent literature and clinical guidelines.

Epidemiology / Disease Burden

Polypharmacy is highly prevalent in older adults and those with multiple chronic conditions, with studies indicating that up to 40-50% of elderly patients take five or more medications concurrently. In the United States, it is estimated that over 30% of older adults are exposed to potentially inappropriate medications. The burden of ADEs associated with polypharmacy contributes significantly to hospitalizations, morbidity, and healthcare costs globally. The World Health Organization has identified medication safety as a key patient safety challenge, emphasizing the urgent need for systematic approaches like medication burden screening to address this epidemic.

Pathophysiology

Medication burden arises from the interplay of pharmacokinetic and pharmacodynamic factors that are accentuated in the context of polypharmacy. Age-related physiological changes, such as decreased renal and hepatic function, altered body composition, and impaired homeostatic mechanisms, increase the susceptibility to drug accumulation and toxicity. Drug-drug and drug-disease interactions further compound the risk, leading to unpredictable therapeutic responses and potential harm. The cumulative anticholinergic, sedative, and cardiovascular load can also precipitate functional decline, delirium, falls, and other adverse outcomes, particularly in vulnerable populations.

Risk Factors

Key risk factors for medication burden include advanced age, multimorbidity, cognitive impairment, renal or hepatic insufficiency, history of falls or ADEs, and the use of high-risk medications such as anticoagulants, antipsychotics, or sedative-hypnotics. Social determinants, such as limited health literacy, polyprovider care, and fragmented care transitions, also contribute to increased risk. Identification of these risk factors through targeted screening can inform individualized deprescribing and medication optimization strategies.

Clinical Features

Patients experiencing high medication burden may present with nonspecific symptoms such as confusion, dizziness, fatigue, falls, gastrointestinal disturbances, and functional decline. These presentations are often underrecognized as being related to medication effects, highlighting the importance of systematic screening and clinical vigilance. The use of validated tools, such as the Medication Regimen Complexity Index (MRCI) and the Drug Burden Index (DBI), can help quantify medication burden and stratify risk in routine care.

Diagnosis

The diagnosis of clinically significant medication burden involves a comprehensive medication review, incorporating patient history, current prescription and non-prescription drug use, assessment of adherence, and identification of potential interactions. Screening tools such as the STOPP/START criteria, Beers Criteria, and the aforementioned indices provide structured frameworks for identifying inappropriate prescribing, therapeutic duplications, and medications that may be discontinued or substituted. Engaging patients in shared decision-making and obtaining collateral information from caregivers further refines diagnostic accuracy.

Treatment & Management

Management of medication burden centers on individualized deprescribing, therapeutic simplification, and ongoing monitoring. Multidisciplinary medication review, involving pharmacists, primary care providers, and specialists, is recommended to ensure that each medication has a clear indication, is evidence-based, and aligns with patient goals. Deprescribing protocols should balance the risks of withdrawal or untreated disease against the potential for ADE reduction. Patient education, regular follow-up, and the use of medication reconciliation during care transitions are essential components of effective management.

Recent Advances / Emerging Therapies

Recent advances in medication burden screening include the integration of clinical decision support systems (CDSS) within electronic health records, enabling real-time identification of high-risk regimens and automated alerts for potential interactions. Artificial intelligence and machine learning approaches are being developed to predict ADE risk and optimize pharmacotherapy at the point of care. There is also growing evidence supporting the routine use of validated screening tools in diverse clinical settings, including primary care, geriatrics, and transitions of care, to systematically reduce medication-related harm.

Guideline Recommendations

International guidelines, such as those from the American Geriatrics Society and the National Institute for Health and Care Excellence, advocate for regular medication reviews and the use of structured screening tools to identify and mitigate medication burden. Key recommendations include prioritizing high-risk populations for screening, employing validated assessment instruments, involving multidisciplinary teams, and integrating patient preferences in decision-making. Ongoing education and support for clinicians are emphasized to sustain best practices in medication optimization.

Conclusion

Medication burden screening represents a vital component of safe and effective pharmacotherapy, particularly in populations vulnerable to polypharmacy-related harms. By leveraging evidence-based screening tools, embracing multidisciplinary collaboration, and adhering to guideline recommendations, healthcare professionals can proactively identify at-risk patients, optimize medication regimens, and enhance clinical outcomes. Continued innovation in screening methodologies and implementation science will be pivotal in further reducing the global burden of medication-related adverse events.